-
Media ReleaseNovartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
-
Media ReleaseNovartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
-
Media ReleaseNovartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
-
Media ReleaseNovartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
-
Media ReleaseNovartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
-
Media ReleaseNovartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program
-
Media ReleaseNovartis commits to addressing racial disparities in breast cancer screening, treatment and care
-
Media ReleaseNovartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media ReleaseNovartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
-
Media ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Media ReleaseNovartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF